A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 12, Issue 4, 2013, Pages 248-254

  Wainberg, Zev A ^a   Messersmith, Wells A ^b   Peddi, Parvin F ^a   Kapp, Amy V ^c   Ashkenazi, Avi ^c   Royer Joo, Stephanie ^c   Portera, Chia C ^c   Kozloff, Mark F ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Apo2L TRAIL; Apoptosis; Death receptor; Dulanermin; FOLFOX; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DULANERMIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUSHING; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; INFUSION RELATED REACTION; LUNG EMBOLISM; MALE; MAXIMUM TOLERATED DOSE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; MULTIPLE DRUG DOSE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

APO2L/TRAIL; APOPTOSIS; DEATH RECEPTOR; DULANERMIN; FOLFOX; METASTATIC COLORECTAL CANCER;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84887317904     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2013.06.002     Document Type: Article

References (24)

1. Cancer Facts & Figures. Available at: http://www.cancer.org/Research/ CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2012. Accessed: December 6, 2012.
2. H.S. Hochster, L.L. Hart, and R.K. Ramanathan Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study J Clin Oncol 26 2008 3523 3529
3. E. Van Cutsem, F. Rivera, and S. Berry Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann Oncol 20 2009 1842 1847
4. A. Ashkenazi Directing cancer cells to self-destruct with pro-apoptotic receptor agonists Nat Rev Drug Discov 7 2008 1001 1012
5. A. Ashkenazi Targeting death and decoy receptors of the tumour-necrosis factor superfamily Nat Rev Cancer 2 2002 420 430
6. L.A. Tartaglia, and D.V. Goeddel Two TNF receptors Immunol Today 13 1992 151 153
7. S.R. Wiley, K. Schooley, and P.J. Smolak Identification and characterization of a new member of the TNFfamily that induces apoptosis Immunity 3 1995 673 682
8. R.M. Pitti, S.A. Marsters, and S. Ruppert Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family J Biol Chem 271 1996 12687 12690
9. G. Pan, K. O'Rourke, and A.M. Chinnaiyan The receptor for the cytotoxic ligand TRAIL Science 276 1997 111 113
10. J.P. Sheridan, S.A. Marsters, and R.M. Pitti Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors Science 277 1997 818 821
11. A. Ashkenazi, R.C. Pai, and S. Fong Safety and antitumor activity of recombinant soluble Apo2 ligand J Clin Invest 104 1999 155 162
12. S.K. Kelley, and A. Ashkenazi Targeting death receptors in cancer with Apo2L/TRAIL Curr Opin Pharmacol 4 2004 333 339
13. R.S. Herbst, S.G. Eckhardt, and R. Kurzrock A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer J Clin Oncol 28 2010 2839 2846
14. L. Yee, M. Fanale, and K. Dimick A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma J Clin Oncol 25 Suppl 2007 Abstr. 8078
15. J.C. Soria, E. Smit, and D. Khayat Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer J Clin Oncol 28 2010 1527 1533
16. L. Yee, H. Burris, and M. Kozloff Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI (with or without bevacizumab) in previously treated metastatic colorectal cancer subjects J Clin Oncol 30 Suppl 2009 abstr 4129
17. J.C. Soria, Z. Mark, and P. Zatloukal Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non- small-cell lung cancer J Clin Oncol 2011 294442 294451
18. DCTD, NCI, NIH, DHHS (2006) Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events Version 3.0.
19. S. Kasubhai, J. Bendell, and M. Kozloff Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC) J Clin Oncol 30 Suppl 2012 Abstr 3543
20. D. Belada, J. Mayer, and M.S. Czuczman Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL) J Clin Oncol 28 Suppl 2010 Abstr 8104
21. J.V. Pawel, J.H. Harvey, and D.R. Spigel A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC J Clin Oncol 28 Suppl 2010 Abstr LBA7501
22. A.L. Cohn, J. Tabernero, and J. Maurel Conatumumab (CON) plus FOLFIRI (F) or ganitumab (GAN) plus F for second-line treatment of mutant (MT)KRAS metastatic colorectal cancer (mCRC) J Clin Oncol 30 Suppl 4 2012 Abstr 534
23. K.W. Wagner, E.A. Punnoose, and T. Januario Death- receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL Nat Med 13 2007 1070 1077
24. Y. Pan, R. Xu, and M. Peach Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours Br J Cancer 105 2011 1830 1838